LGVN
Longeveron Inc.0.5528
+0.0025+0.45%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
11.79MP/E (TTM)
-Basic EPS (TTM)
-0.98Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Nasdaq compliance warning issued
Longeveron Inc. received a Nasdaq notice on September 22, 2025, for failing the $1.00 minimum bid price requirement over 30 consecutive business days, triggering a 180-day compliance window until March 23, 2026. The company plans to monitor its stock price and explore options to regain listing eligibility, but faces risks of delisting if the bid drops to $0.10 or below for ten days. No assurance of success.
8-K
ATM offering for $10.7M
Longeveron Inc. entered an at-the-market offering agreement with H.C. Wainwright & Co. on September 19, 2025, enabling sales of up to $10,700,000 in Class A common stock through Nasdaq or negotiated deals. Proceeds will fund clinical development of laromestrocel for Hypoplastic Left Heart Syndrome, Alzheimer's, and Pediatric Dilated Cardiomyopathy, plus working capital. No sales are guaranteed. Dilution looms for shareholders.
ANVS
Annovis Bio, Inc.
3.93+0.15
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
FBLG
FibroBiologics, Inc.
0.24-0.02
GERN
Geron Corporation
1.34+0.01
LBRX
LB Pharmaceuticals Inc
19.82-0.04
RMTG
Regenerative Medical Technology
0.04+0.00
SEOVF
SERNOVA BIOTHERAPEUTICS INC.
0.10+0.00
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02
VCEL
Vericel Corporation
35.50-0.99